Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy - 09/08/11
Reprint requests: Andrew L. Ondo, MD, 4351 E Lohman Ave, Suite 208, Las Cruces, NM 88011.Las Cruces, New Mexico; Boise, Idaho; Brunswick, Ohio; and New York, New York
Abstract |
Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream. Such treatment may be preferable to surgical or destructive modalities in certain anatomic locations and in instances where patients are unwilling or poor surgical candidates. We present 4 such patients with cutaneous squamous cell carcinoma in situ involving a digit. Each patient failed treatment with imiquimod cream as monotherapy. In addition, two patients failed treatment with 5-fluorouracil cream as monotherapy. All 4 responded completely to 5-fluorouracil and imiquimod cream as combination therapy. In patients who have failed monotherapy with a topical agent for cutaneous squamous cell carcinoma in situ, combination treatment using both topical 5-fluorouracil cream and imiquimod cream may be considered as an alternative therapeutic strategy.
Le texte complet de cet article est disponible en PDF.Abbreviations used : IFN, IL, SCC, TLR
Plan
| Funding sources: None. Disclosure: Dr Mings is a speaker for 3M, the manufacturer of imiquimod. |
Vol 55 - N° 6
P. 1092-1094 - décembre 2006 Retour au numéro
Article précédent
- “Fat fingers:” A clue in the dermoscopic diagnosis of seborrheic keratoses
- Alfred W. Kopf, Harold Rabinovitz, Ashfaq Marghoob, Ralph P. Braun, Steven Wang, Margaret Oliviero, David Polsky
- Acremonium mycetoma in a heart transplant recipient
- Adam S. Geyer, Lindy P. Fox, Sameera Husain, Phyllis Della-Latta, Marc E. Grossman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?